-
Kizdar net |
Kizdar net |
Кыздар Нет
- The DanGer Shock trial showed that routine implantation of Impella CP on top of standard care is superior to standard care alone in reducing 6-month mortality among patients presenting with STEMI and cardiogenic shock, despite a higher risk of complications.
www.acc.org/latest-in-cardiology/clinical-trials/2024/04/05/04/44/danger-shock Microaxial Flow Pump or Standard Care in Infarct-Related …
Apr 7, 2024 · We performed the Danish–German Cardiogenic Shock (DanGer Shock) trial to test the hypothesis that routine use of a microaxial flow pump in addition to standard guideline …
See results only from nejm.orgMicroaxial Flow Pump in Infarct-Related Cardiogenic Shock
To the Editor: The Danish–German Cardiogenic Shock (DanGer Shock) trial conducted by Møller et al. (April 18 issue) 1 showed a reduction in al…
DanGer Shock: Impella CP Improves Survival After …
Dec 19, 2024 · Implantation of the Impella CP micro-axial flow pump may increase survival at six months among patients with STEMI complicated by cardiogenic shock (CS), according to the results of the DanGer Shock study, …
Microaxial Flow Pump in Infarct-Related Cardiogenic Shock
Apr 7, 2024 · The DanGer Shock trial showed that routine implantation of Impella CP on top of standard care is superior to standard care alone in reducing 6-month mortality among patients …
Long-Awaited RCT Data Show Survival Benefit With …
Apr 7, 2024 · For DanGer Shock, investigators screened 1,211 potential participants, ultimately randomizing 360 patients with AMICS across 14 centers to receive standard care alone or with the addition of the Impella CP microaxial …
Microaxial Flow Pump Use and Renal Outcomes in Infarct …
Oct 27, 2024 · In DanGer Shock (the Danish–German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment–elevation myocardial …
Apr 7, 2024 · In an international, multicenter, randomized trial, we assigned patients with STEMI and cardiogenic shock to receive a microaxial flow pump (Impella CP) plus standard care or …
- People also ask
the DanGer Shock trial. Results The primary study endpoint is death from all causes through 180 days in the intention to treat population (all randomized consented patients).
Microaxial Flow Pump in Infarct-Related Cardiogenic Shock
Jun 26, 2024 · To the Editor: The Danish–German Cardiogenic Shock (DanGer Shock) trial conducted by Møller et al. (April 18 issue) 1 showed a reduction in all-cause mortality with the …
Danish-German cardiogenic shock trial-DanGer shock: Trial
Results: The primary study endpoint is death from all causes through 180 days in the intention to treat population (all randomized consented patients).
Percutaneous Transvalvular Micro-Axial Flow Pump in Infarct
Apr 9, 2024 · The DANGER SHOCK trial was conducted to evaluate the efficacy of the transvalvular axial flow device, Impella CP (Abiomed, Danvers, Washington) in treating …
DanGer Shock: Older Patients Exhibit Greater Risk of Mortality …
Jan 6, 2025 · Older patients with STEMI-related cardiogenic shock have a greater risk of mortality and may not experience the same benefit from microaxial flow pump (mAFP) treatment as …
DanGer Shock: Impella Reduces All-Cause Mortality in STEMI
Apr 10, 2024 · The DanGer Shock trial (NCT01633502) was an international, multicenter, randomized trial examining Impella CP vs standard of care in AMI-CS. Participants were …
Perspectives on why DanGer Shock is the first positive trial on ...
Dec 11, 2024 · The results of the DanGer Shock trial stand out compared with the outcomes of the previous trials and mark the first mechanical circulatory support (MCS) strategy to show a …
Percutaneous transvalvular micro-axial flow pump in infarct …
Apr 7, 2024 · Results show that the implantation of microaxial flow pump post-heart attack significantly boosts survival in patients with STEMI-related cardiogenic shock, though with …
DanGer Shock Results from Dr. Jacob Møller at ACC 2024
Nov 14, 2024 · Dr. Møller explains that DanGer Shock was designed for patients with predominantly left ventricular (LV) failure and acute myocardial infarction (AMI) cardiogenic …
DanGer Shock Results at ACC 2024 from Jacob Møller, M.D.
Jacob Møller, M.D., the principal investigator of the DanGer Shock trial, discusses study results he presented at the 2024 American College of Cardiology (ACC) Scientific Session in this …
Ripped From the Headlines of ACC: DanGer Shock RCT Results
Sep 24, 2024 · The DanGer Shock trial provides unequivocal evidence for the use of Impella to reduce mortality and LV dominant STEMI shock.” He also states, “one of the most important …
Rationale and design of DanGer shock: Danish-German …
Aug 1, 2019 · The DanGer Shock trial will be the first adequately powered randomized trial to address whether mechanical circulatory LV support with Impella CP can improve survival in …
Danish-German cardiogenic shock trial—DanGer shock: Trial …
Jan 1, 2023 · The main objective of the DanGer Shock trial is to assess the efficacy of the trans valvular axial flow device Impella CP (Abiomed, Danvers, MA) in treating patients with AMICS …
DanGer Shock Randomized Control Trial FAQs
Oct 22, 2024 · How will the results of the DanGer Shock trial impact patient care today? DanGer Shock results highlight the first treatment strategy to show benefit in patients with AMICS since …
Related searches for danger shock trial results
Skip to content
